<DOC>
	<DOCNO>NCT00888758</DOCNO>
	<brief_summary>The primary objective study : - comparison safety effectiveness third generation DES ( biolimus A9 everolimus ) patient STEMI treat primary PCI OCT guidance . A rate 9 month MACE ( death , myocardial infarction , ischemia driven TLR ) assess group . The secondary outcome comparison ( use OCT ) : - number uncovered stent strut - number malapposed stent strut - in-stent neointimal volume - in-segment assessment vessel wall response DES</brief_summary>
	<brief_title>Comparison Biolimus A9 Everolimus Drug-Eluting Stents Patients With ST Segment Elevation Myocardial Infarction</brief_title>
	<detailed_description>The aim multicenter , prospective , randomized trial core lab analysis ass safety effectiveness ( 9-month follow-up ) third generation DES ( biolimus A9 everolimus ) patient evolve STEMI OCT guidance ( optimize stent implantation ) A serial OCT analysis perform assess number either uncovered malaposed stent strut degree in-stent neointimal hyperplasia . Furthermore , in-segment vessel wall response DES implantation also analyse . The goal enroll 400 patient ( 200 group ) OCT guidance 100 patient group .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Acute STEMI within 12 hour symptom onset 2 . Native coronary disease lesion suitable stenting 3 . Vessel size 2.53.75mm 4 . Patient willing provide write informed consent 5 . Male female patient 1885 year age 1 . Significant leave main disease 2 . Killip class IV 3 . Known allergy aspirin clopidogrel/ticlopidine 4 . Recent bleeding ( &lt; 1month ) 5 . Patient anticoagulant therapy 6 . No suitable coronary anatomy OCT scan ( ostial lesion , distal large vessel / &gt; 3.75mm diameter/ ) 7 . Pregnancy 8 . Severe liver renal disease ( Cr &gt; 2.0 ) 9 . Life expectancy &lt; 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Stents</keyword>
</DOC>